In this review
The product cards are the useful price reference
LaSara’s semaglutide page lists a $289 monthly subscription, a $299 one-month plan, $849 for three months, $1,495 for six and $2,795 for twelve. Tirzepatide is $379 monthly by subscription, with separate one-, three-, six- and twelve-month plans at $399, $1,100, $1,995 and $3,895. [1] [2]
The About page instead advertises semaglutide from $179 per month. That does not explain which preparation, supplied quantity or eligibility produces that price alongside the current product grid. Longer-plan equivalents are not proof of monthly installments. Establish the initial charge and renewal calendar before deciding which option is cheaper. [1] [2] [3]
Compare the invoice and renewal together in the GLP-1 total-cost planner.
Coaching is a real feature to specify
The weight-care page describes one-to-one metabolic-health support, coaching by clinicians and product specialists, and free shipping without a separate monthly membership. The semaglutide page describes delivery, monitoring and proactive check-ins as included. These features make LaSara more than an isolated prescription request. [1] [4]
Tirzepatide separately describes monthly delivery, proactive physician check-ins and laboratory monitoring. Confirm which tests, collection fees and appointments the selected plan includes; that wording does not establish a complete free panel. Nor does around-the-clock support identify a guaranteed clinician response time or recurring registered-dietitian appointment. [2] [3]
Compare a different appointment-led service in our Form Health continuing-care review.
Cancel anytime needs an order policy
The product grids promise the ability to cancel or pause anytime. Their linked public Terms & Conditions address website use, rather than the cutoff for an existing prescription order or the handling of refunds after medical review. Get the applicable purchase agreement, including non-approval and shipment-problem remedies. [1] [2] [5]
The November offer is up to 30% off a first order through November 30, subject to the selected purchase. It should not be deducted from every published price or carried forward to renewals. Separate financing logos also do not establish approval, interest or the amount payable today. [1] [2]
For explicitly stated fees and cancellation conditions, read the Telezen MD refund review.
Compare another provider’s stated supply and cancellation agreement in our Nova MD plan-and-terms review.
Keep the supplied formulation separate from the trial story
LaSara names compounded semaglutide and tirzepatide and describes pharmacy sourcing. A logo or broad purity claim does not identify the actual dispenser, ingredients, concentration and amount in a particular order. Those details belong beside the written quote and clinical plan. [1] [2]
Compounded drugs are not FDA-approved generic equivalents. FDA’s post-shortage compounding conditions remain patient-specific; branded trial results do not verify the supplied preparation. I would shortlist LaSara for its described continuing care only after the product, coaching access and financial commitment are specified together. [6] [7]
Keep the body-composition question distinct from provider marketing with the GLP-1 lean-mass evidence.
Understanding the cost
Semaglutide subscription $289/month; separate 1/3/6/12-month plans $299/$849/$1,495/$2,795. Tirzepatide subscription $379/month; separate plans $399/$1,100/$1,995/$3,895. About-page $179 teaser not the current product invoice. Confirm preparation, fees, initial charge, supply and renewal.
Build your cost estimateSources
- LaSara: compounded semaglutide plan totals and included clinical support
- LaSara: compounded tirzepatide plans, check-ins and laboratory-monitoring description
- LaSara: subscription teaser, coaching, shipping and service catalogue
- LaSara: weight-care support and coaching model
- LaSara: public website terms and national telehealth description
- FDA: compounded drugs and premarket approval limits
- FDA: patient-specific GLP-1 compounding conditions after shortage resolution
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.